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Abstract
Global rate of participation in clinical trials is especially low among African Americans
in the United States due to social factors identified by research, which adversely impact
this group’s willingness to participate in clinical trials. The purpose of this cross-sectional
quantitative study was to evaluate the role of social influence in the decision-making
patterns of African Americans as it relates to clinical trial participation. The theory of
planned behavior was used as the theoretical framework to understand an individual’s
interaction with social factors and how it affects their willingness to participate in clinical
trials. The participants in the study were 115 African Americans residing in a greater
metropolitan area of Ohio. Data were collected using 1-time questionnaire administered
by paper instrument. Regression and correlation analyses were conducted for all 115
collected survey responses. Results of the analyses were statistically significant in
proving that social influence is a good predictor of willingness to participate in clinical
trials where the research involves minimal risk to the participants (p = 0.047). The results
also showed that attitudes and beliefs about clinical trials are good predictors of
willingness to participate in clinical trials among African Americans (p = 0.000). The
results of this study offer new insight for the development of patient recruitment
initiatives within the African American community in the United States and create a path
to the development of viable and sustainable intervention.
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Chapter 1: Introduction to the Study
Introduction
Clinical trials explore the safety and efficacy of novel drugs or devices used in the
treatment of new or existing diseases in humans and highlights the best medical treatment
that best serves a certain group of people (National Institutes of Health [NIH], 2017).
There is a general acceptance by the medical community as well as the public of the
importance of advancing medical knowledge (Center for Information & Study on Clinical
Research Participation, 2012; Steinke, 2004). Notwithstanding these facts, together with
the overall acceptance of the benefits of clinical trials, global rates of clinical trials
participation is low in the United States (Lee, Ow, Lie, & Dent, 2016). This issue is of
great concern, particularly among African Americans and other ethnic minorities, and
little or no improvement has been recorded over the years (Hughes, Varma, Pettigrew, &
Albert, 2017; Lang et al., 2013). Clinical trial participation numbers have seen a decrease
in the past 30 years, a decline which is expected to continue in the coming years (Galea &
Tracy, 2007; Rogers, Murtaugh, Edwards & Slattery, 2004).
The burden of disease data in the United States confirms that African Americans
stand a higher risk of morbidity and early mortality than other races (Noonan, VelascoMondragon, & Wagner, 2016). Research has shown that race and ethnicity are correlated
with the growing health disparities in the United States (Noonan, Velasco-Mondragon, &
Wagner, 2016). Nonetheless, there is an increase in the lack of willingness to participate
in clinical trials and recruitment of African Americans for participation in these trials
continues to be a discouraging task (Anwuri et al., 2013). There is a need for more
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research into the factors that are specific to the African American population, including
the behaviors that promote the lack of willingness to participate in clinical trials in the
United States. The inability to develop a viable strategy to overcome this issue raises a
concern regarding the future of clinical trials that are generalizable to all races and
ethnicities in the United States (Hughes et al., 2017).
The problem of low ethnic minority participation in clinical trials is significant to
public health because adequate therapies to cure illnesses result from extensive research
in the targeted population. African American representation in clinical trials is needed
because they have a greater risk of morbidity and early mortality compared to other races
in the United States (Noonan et al., 2016), and race and ethnicity correlates with the
rising health inequalities in the United States (Fisher & Kalbaugh, 2011). Research that is
considered ethical and scientifically sound must include a sample population that is
representative of the population (George, Duran, & Norris, 2014; Hughes et al., 2017).
Willingness represents an individual’s inclination or favorable mental disposition
towards an action (“Willingness,” 2017). African Americans differ from European
Americans and other ethnic groups in their willingness to participate in clinical trials, and
this issue has been attributed to a host of factors including a low level of trust of medical
research (Bruce et al., 2014; Tanner, Kim, Friedman, Foster, & Bergeron, 2015).
Previous research studies have provided conclusions that suggest a link between social
factors operating within a group and their willingness to participate in clinical trials
(Bruce et al., 2014; Tanner et al., 2015). In a literature review conducted by Luebbert and
Perez (2016), the authors reported that the barriers to willingness to participate in clinical
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trials among African Americans included issues related to trust, experimentation,
communication, and logistics. Hughes et al. (2015) concluded that fear and lack of trust
for research were the most common barriers to participation in clinical trials among
African Americans. These barriers were attributed to factors like lack of information
related to the research and prevailing knowledge of historical instances of unethical
research practices (Hughes et al., 2015). Other social factors like racism (Sherman,
Hawkins, & Bonner, 2017; Speights et al., 2017), attitudes towards research (Bruce et al.,
2014), fear of being used as guinea pigs (Hughes et al., 2015; Tanner et al., 2015), and
socioeconomic status (Chen, Lara, Dang, Paterniti, & Kelly, 2014; Unger et al., 2013)
have also been identified.
The younger generation of African Americans who have not directly experienced
or have direct evidence of unethical practices against ethnic minorities may rely on
inaccurate information as it relates to clinical trials, passed on from parents or older,
earlier generations through storytelling (Lee, Fawcett, & DeMarco, 2016; Palacios et al.,
2015). The authority influence hypothesis proposed by Schöbel, Rieskamp, and Huber
(2016) predicts that
people’s behavior will also be influenced by the hierarchical status of other
decision makers and will make decisions that conform to higher ranked others’
decisions more often, even if other available public information and their own
private information suggest doing otherwise (p. 5).
According to Hughes et al. (2015), one of the most commonly identified barriers to
participation is the historical occurrences of past unethical research practices. Through an
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individual’s interaction with these sociocultural factors, these valid historical occurrences
could easily be mixed up with urban legends and then passed down through generations
in the African American community (Hughes et al., 2015).
Social influence represents the changes in behavior, opinion, or beliefs that
individuals initiate, based on interactions with the prevailing social factors (Moussaïd,
Kämmer, Analytis, & Neth, 2013). It represents the process through which an individual
can adapt their opinions, revise their beliefs, or adjust their behavior, resulting from
social interactions with others (Moussaïd, Kämmer, Analytis, & Neth, 2013). The role of
social influence in potentially diminishing the willingness of African Americans to
participate in clinical trials is not well established. Due to unfavorable health outcomes in
the African American community, it is important to identify the process by which the
history of unethical practices against this population continues to be at the forefront of all
identifiable barriers to research, despite great advances in research participant protections
and research ethics in the United States. The answer to this could lie in an African
American’s recognition of the activities that apply to them based on their desire to
conform to a behavior or norm developed through sociocultural values (Moussaïd et al.,
2013).
The barriers to African American participation in clinical trials have been
examined by different researchers (e.g., Anwuri et al., 2013; George et al., 2014; Lee et
al., 2016). However, these barriers have not been effectively linked to the ever-present
impact of social influence. More research is needed to evaluate trends that support the
role played by social influence in either encouraging or discouraging the willingness of
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African Americans to participate in clinical trials because an individual’s social
conditions, environmental exposures, and past experiences work together to produce
behavior and motivation (see Garza et al., 2017; Moussaïd et al., 2013). Common
opinions are created by common cultural beliefs, and according to Moussaïd et al. (2013),
opinions are more likely to be reinforced by group discussions conducted by individuals
with similar judgement. The results of this study provide much needed insight into this
issue that impacts health promotion because failure to increase the participation rates of
African Americans in clinical trials will inhibit the progress of clinical trial research into
novel and effective methods in drug development (see Frew, Schamel, O’Connell,
Randall, & Boggavarapu, 2015).
Background of the Problem
African Americans represent approximately 13.3% of the U.S. population (U.S.
Census Bureau, 2016) and continue to experience an unequal burden of disease, limited
access to health and health care services, and lower life expectancy when compared to
other races (Correa-de-Araujo, 2017; Frist, 2005). When compared to other races,
African Americans differ unfavorably in their willingness to participate in clinical trials
(Kurt et al., 2016; Shavers, Lynch, & Burmeister, 2002), representing only 5% of all
clinical trials participants in the United States (Hughes et al., 2015). This issue has been
attributed to a host of factors, including distrust for medical research (Kurt et al., 2016;
Shavers et al., 2002; Stuchlik et al., 2015), resulting from a history of unethical practices
and harsh treatments that were meted out to the African Americans (e.g., the Tuskegee
Study; Durant, Legedza, Marcantonio, Freeman, & Landon, 2011). Several researchers
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have proposed that the distrust resulting from the Tuskegee Study is the major
impediment for the willingness of African Americans to participate in clinical trials
(Sacks, 2015). Shavers, Lynch and Burmeister (2000) reported that 81% of the 179
African American adult participants in their study had knowledge of the Tuskegee Study.
The researchers also found that this knowledge directly influences their level of trust for
medical research (Shavers et al., 2000). Knowledge of historical instances of unethical
practices is further compounded by present feelings of comparable mistreatment
Although there is a mandate by federally funded agencies to include racially
diverse populations in clinical trials, the enrollment of African Americans in clinical
trials remains a discouraging task (Hughes et al., 2015). Data shows that although African
Americans make up 12.4% of the entire U.S. population, only 5% of clinical trials
participants in the United States are African Americans (Fisher & Kalbaugh, 2011;
Hughes et al., 2015). The current gap in research needed to understand this issue and the
inadequacy in the development of a practical approach to overcome the issue raises a
concern regarding the future of research into treatments for race-specific diseases like
sickle cell disease, as well as concern for the ability of researchers to generalize clinical
trials results to the entire population (Hughes et al., 2015).
It is important to understand the impact of social influence, an intricate inherent
human factor that holds the potential to impact attitudes and behaviors, on the decisionmaking patterns and the willingness to participate in clinical trials among African
Americans. An individual’s partner or family members can influence their willingness to
participate in clinical trials, and this was concluded to be greater in clinical trials
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conducted in developing countries than in developed countries (Lobato et al., 2014). This
finding was attributed to the influence of culture identification, which promotes
interdependence (Lobato et al., 2014). In a multicenter study of hypertension and genetics
by Marshall et al. (2006), 47% of female participants enrolled in Nigeria solicited the
guidance of their partners prior to participating in the research compared to the U.S.enrolled female participants of which none solicited the advice of a partner before
participation. Banks-Wallace (2002) reported that storytelling, which is a part of the core
of the African American culture, can also affect behavior. When life events or
experiences are considered, this process of storytelling could create a communal
experience that links the teller to the listener, thereby promoting similar behavior and
attitudes (Banks-Wallace, 2002). The mistrust exhibited by African Americans for
healthcare services and healthcare providers as well as other institutions has survived
many generations.
With this study, I shed light on the existence of the concept that social influence,
as an intricate inherent human factor, holds the potential to impact attitudes and behaviors
related to willingness to participate in clinical trials. The results of this study provide a
better understanding of the positive and/or negative impact of social influence factors
(i.e., culture, beliefs, values, attitudes, and learned individual preferences) on clinical
trials and contribute to ongoing research into developing methods to maximize ethnic
minority participation in clinical trials in the United States (see Branson, Davis, & Butler,
2007). Some research studies aimed at identifying barriers to participation in clinical
trials among African Americans have been replicated without specifically capturing and
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assessing the role played by social influence, a core factor when evaluating behaviors
within a culturally unique population, thus making my research the logical next step to
assess how social factors may influence willingness. (see Marshall et al., 2006). In this
study, I looked at the impact of social influence on an African American’s willingness to
participate in clinical trials. The findings of the study shed light on how information
passed from generation to generation through storytelling affects current behaviors
related to research participation decisions and lends significance to a common goal of
equity and equality in health care services and delivery.
Problem Statement
There is an unequal burden of disease, limited access to health and health care
services, and lower life expectancy among African Americans when compared to other
races (Frist, 2005). This issue is worsened by a systemic underrepresentation of African
Americans in clinical trials, including clinical trials which target race-specific diseases
(e.g., sickle cell disease), culminating in shortfalls in data generated from clinical trials
and limiting the ability of researchers to generalize the results to the entire U.S.
population (Frist, 2005). Information regarding the impact of newly developed therapies
used in the treatment of diseases that affect the African American population is limited,
and although there are government regulations aimed at enforcing ethnic minority
participation in government-funded research, African Americans as well as other
minorities remain underrepresented in important clinical trials (Sanders, 2011).
Therefore, the problem I addressed in this study was the inability of researchers to
generalize clinical trial results and to develop new therapies targeting diseases that are
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prevalent in the African American population. I addressed this issue by identifying the
role played by social influence and its effectiveness and potential use in the development
of viable interventions.
Purpose of the Study
I designed this study to identify how social influence affects the willingness of
African Americans to participate in clinical trials as a platform for the development and
implementation of interventions to improve clinical trial participation among this
population. In this study, I methodically examined and elucidated the potential
association between the willingness of African Americans to participate in clinical trials
and predisposing variables that included social influence and other demographics (i.e.,
gender, age, employment status, and family history of research participation; Chen et al.,
2014). The theory of planned behavior was used as the framework to guide the research
questions.
Study Population
The population for this study included African Americans, aged 18 years and
older, who resided in a greater metropolitan area of Ohio. In this study, I defined African
Americans as individuals who are Black and are of African descent and who identify as
Black, African, or African American. This definition ensured the inclusion of a broader
range of individuals for the study.
The racial make-up of the city is 49.3% White, 44.8% Black or African
American, 1.8% Asian, 2.8% Hispanic or Latino, and 0.3% American Indian or Native
Americans (U.S. Census Bureau, 2017). The population of people 18 years or older in the
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city is 232,150, of which African Americans make up 41% (U.S. Census Bureau, 2017).
1.8

2.8

0.3

White
Black/African American
49.3

Asian
Hispanic

44.8

American Indian/Native American

Figure 1. Racial demographics (U.S. Census Bureau, 2017)

Of the 30.5% of the city’s population who live below the poverty line, 42.3% are
African Americans (U.S. Census Bureau, 2017). There are mixed reports regarding the
impact of socioeconomic status on health care trust among African Americans
(Hammond, 2010; Rajakumar, Thomas, Musa, Almario, & Garza, 2009; Watkins et al.,
2012). However, Guerrero, Mendes de Leon, Evans, and Jacobs (2015), in a study
exploring the differences in socio-demographic and psychological correlates of
institutional trust in health care among older African Americans and other minorities,
concluded that psychological factors played a more prominent role in health disparities
among older African Americans. Social interactions and the impact of the environment
were identified as major players in the level of trust in health care (Guerrero et al., 2015).
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Research Questions and Hypotheses
The research questions I developed for this study were primarily focused on the
socio-cultural factors that influence the willingness to participate in clinical trials among
African Americans aged 18 years and older. The following research questions and
corresponding hypotheses guided this dissertation:
Research Question 1: What is the relationship between knowledge of clinical
trials and willingness to participate in clinical trials among African Americans?
H01: There is no statistically significant relationship between knowledge
of clinical trials and willingness to participate in clinical trials among
African Americans.
HA1: There is a statistically significant relationship between knowledge of
clinical trials and willingness to participate in clinical trials among African
Americans.
Research Question 2: What is the relationship between attitude and beliefs and
willingness to participate in clinical trials among African Americans?
H02: There is no statistically significant relationship between attitude and
beliefs and willingness to participate in clinical trials among African
Americans.
HA2: There is a statistically significant relationship between attitude and
beliefs and willingness to participate in clinical trials among African
Americans
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Research Question 3: Does social influence within the African American
community affect the willingness of an African American to participate in clinical
trials?
H03: There is no statistically significant relationship between social
influence within the African American community and the willingness of
an African American to participate in clinical trials.
HA3: There is a statistically significant relationship between social
influence within the African American community and willingness of an
African American to participate in clinical trials.
Assumptions
My first assumption for this study was that the validated survey instrument would
be fully completed by all research participants once administered. I also assumed that
research participants would have the necessary educational level to read and understand
the content of the survey with no difficulty and that they would truthfully answer the
questions. Another assumption was that the lack of willingness to participate in clinical
trials is a known phenomenon within the African American community and may have
limited the participation rates in this study. Finally, I assumed that the results of this
research could provide guidance for the development of interventions aimed at improving
African Americans participation in clinical trials.
Limitations
I identified some factors that could have limited the findings of this study. These
include the potential for incomplete surveys being submitted by participants as well as a
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possible low level of honesty in the responses. The responses from the participants may
have been influenced by my presence, skewing the results. Another limitation laid in the
fact that the quality of a quantitative research depends profoundly on the researcher’s
efficiencies and is influenced by individual predispositions of the researcher (see
Anderson, 2010). Furthermore, due to the planned data collection method, in which only
church attendees who agreed to participate in the research were included, the results may
not be generalizable to all church attendees in a greater metropolitan area of Ohio.
Although a previous study reported that religiously based differences on social issues are
less evident among African Americans compared to the overall population, with 53% of
African Americans polled reporting attending religious services at least once a week
(Sahgal & Smith, 2016), the results of this study may not be generalizable to the entire
African American population because of differences in opinions that may exist among
church goers vs. non-church goers.
Delimitations
This study included only African Americans residing in a greater metropolitan
area of Ohio. Recruitment of other ethnic groups did not fit in the boundaries of the
study. The choice of the geographic location for this study was based on ease of conduct
and the availability of a higher population of African Americans in the selected area in,
Ohio.
Definition of Terms
African American: An American citizen of Black, African descent (“African
American,” 2017).
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Clinical trial: A process used to evaluate the safety and efficacy of medical
strategy, treatment, or device in humans and that highlights the best medical treatment
that best serves a certain group of people (NIH, 2017).
Social influence: Changes in behavior, opinion, or beliefs that individuals initiate
based on interactions with the prevailing social factors. It represents the process through
which an individual can adapt their opinions, revise their beliefs, or adjust their behavior,
resulting from social interactions with others (Moussaïd, Kämmer, Analytis, & Neth,
2013).
Willingness: An individual’s inclination or favorable mental disposition towards
an action (“Willingness,” 2017).
Implications for Social Change
Failure to increase the participation rates of African Americans in clinical trials
will inhibit the progress of clinical trial research into novel and effective methods in drug
development (Frew et al., 2015). I designed this study to identify how social influence
affects the willingness of African Americans to participate in clinical trials as a platform
for the development and implementation of interventions to improve clinical trial
participation among this population. This study will serve as a starting point for further
research into the interactions stated in the focus of this study.
Summary
Clinical trial participation is an intricate part of advancing medical science and
drug development. Notwithstanding the acceptance by most Americans, the overall
participation numbers continue to see an uncontrolled decline (Anwuri et al., 2013). Low
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rates of participation in clinical trials ultimately impact advancements in medical science,
the health of the nation, and eventually the economy of our nation. In this chapter, I
examined the potential link between the low participation rates among African
Americans and social influence, which represents the process through which an
individual can adapt their opinions, revise their beliefs, or adjust their behavior, resulting
from social interactions with others. An understanding of this interaction will be of
benefit to clinical researchers by enabling the identification and elimination of barriers to
participation among African Americans. In the next chapter I reviewed some existing
literature which highlight results that support the existence of a relationship between
social factors and willingness to participate in clinical trials.

16
Chapter 2: Literature Review
Introduction
In this chapter, I will provide a review of relevant literature related to people’s
willingness to participate in clinical trials and African Americans’ willingness
specifically, focusing on the roles of distrust and other barriers created by the historical
knowledge of unethical practices against African Americans and other ethnic minorities
in the United States. I will also review literature related to the potential effects of
normative social influence and sociocultural norms like generational information sharing
on knowledge, attitude, and beliefs (KAB) towards participation in clinical trials.
Literature related to social norms that impact health behavior will also be reviewed.
The NIH (2017) defined a clinical trial as “A research study in which one or more
human subjects are prospectively assigned to one or more interventions” (p. 4). Clinical
trials (also known as clinical treatment research) is medical research through which
researchers witness the progression of a disease or condition in human beings to assess
the effectiveness of a drug or therapy (Brown & Topcu, 2003). Clinical trials serve to
explore the efficacy and safety of various medicinal treatment strategies in humans (NIH,
2014). The problem of low ethnic minority participation in clinical trials is significant to
public health because there is a greater risk of morbidity and early mortality among
African Americans compared to other races in the United States and race correlates with
the rising health inequalities in the United States (Fisher & Kalbaugh, 2011). I aimed this
systematic literature review at elucidating the interactions between social influence and
willingness to participate in clinical trials. Several factors have been identified by
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researchers that affect willingness to participate in clinical trials including age,
race/ethnicity, gender, socioeconomic status, education, health status, knowledge about
clinical trials, perceived risk or benefit, compensation, altruism, and trust.
Search Strategy
I located the information presented in this literature review using peer-reviewed
journal articles and books found through the EBSCO Research Database, PubMed, and
Google Scholar. I focused on literature published within the past 5 years. My search
strategy for identifying relevant literature consisted of Boolean combinations of the
following terms: social influence, normative social influence, willingness, African
Americans AND clinical trials, African Americans AND clinical research, African
Americans AND clinical trials, barriers to research participation, Tuskegee Study and
distrust, African American AND research willingness, distrust AND research, cultural
distrust, storytelling, historical trauma, social influence, Tuskegee experiment, unethical
experiments AND African-Americans, social distrust, fear of research, and African
American knowledge of research.
Developing Social Influence Concept
Individuals within a community regularly make decisions in a social environment;
they are more likely to adopt the opinion of others while ignoring their own, with little or
no regard to the accuracy of the information (Schöbel et al., 2016). Most human decisions
are made in a framework of highly multifaceted social interactions, and many of an
individual’s decisions are influenced by the behavior of others (Hertz, Romand-Monnier,
Kyriakopoulou, & Bahrami, 2016). Social influence represents the changes in behavior,
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opinion, or beliefs that an individual may initiate based on interactions with the
prevailing social factors and the process through which an individual can adapt their
opinions, revise their beliefs, or adjust their behavior, resulting from social interactions
with others (Moussaïd et al., 2013). There are two types of social influence that are
helpful in explaining human conformity: normative social influence and informational
social influence (Schöbel et al., 2016). The former, which was the focus of this study,
defines behavior motivated by an individual’s desire to achieve an appreciated, clear selfidentity, followed by an expression of a defined impression to others (Schöbel et al.,
2016). The latter defines behavior that is developed from valuable information provided
by another individual’s opinion and used to improve judgement or a decision (Schöbel et
al., 2016).
Although the impact of social influence on the willingness of African Americans
to participate in clinical trials could be positive or negative, my focus in this study was to
understand how social influence serves to deter most African Americans from
participating in clinical trials. Research has documented associations between
sociocultural factors and health; however, the role of social influence in potentially
diminishing the willingness of African Americans to participate in clinical trials is not
well established (Berkman & Kawachi, 2000; Marmot & Wilkinson, 2006).
Since common opinions are created by common cultural beliefs, and per
Moussaïd et al. (2013), opinions are more likely to be reinforced by group discussions
conducted by individuals with similar judgement, it is important to identify the process
by which the history of unethical practices against this population continues to be at the
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forefront of all identifiable barriers to their participation in research, despite great
advances in research participant protections and research ethics in the United States. The
answer to this could be present in African Americans’ recognition of the activities that
apply to them based on their desire to conform to a behavior or norm developed through
sociocultural values (Palacios et al., 2015). There are social factors beyond the memories
of the Tuskegee Study that play a role in negatively influencing African Americans’
willingness to participate in clinical trials (Saleem et al., 2016).
Some researchers have argued that the history of abuse and unethical practices
may not be the direct driver of societal distrust in clinical trials (Durant et al., 2011;
Saleem et al., 2016), making it plausible that social factors (i.e., opportunity, income,
ethnic minority status, and health conditions), which are antecedents of inequity in the
U.S. society, could contribute to African Americans’ lack of willingness to participate in
clinical trials (Lang et al., 2013). An individual’s social conditions, environmental
exposures, and past experiences work together to produce behavior and motivation
(Boulware et al., 2016). Individuals also apply differential weighting to social
information based on the authority of other individuals who are decision makers, and this
influence of authority is at its highest strength when the decision of an individual with
authority contrasts with private information (Schöbel et al., 2016).
Conformity behavior has been shown to be motivated by developing and
maintaining acceptance (Schöbel et al, 2016). The results of this study provide insights
into the effects of the relationship between social influence and the willingness of African
Americans to participate in clinical trials as a benefit to health promotion.
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The Concept of Storytelling
Storytelling is an age-old institution that exists among different communities and
cultures around the world. Information sharing preserves cultural beliefs and practices
from generation to generation, and most people will remember most negative actions
towards them to avoid similar actions in the future (Barton & Barton, 2017). Stories have
been found to play a vital role in the lives of individuals across various age groups and
diverse backgrounds (Barton & Barton, 2017). The impact of storytelling in native
communities is well documented for cultural and historical legacy and communication
(Barton & Barton, 2017). The younger generation can form and build a strong identity
that could potentially affect their ability to develop immediate opinions about wellestablished issues like racism and distrust for the healthcare community (Barton &
Barton, 2017). According to Eder (2010), through storytelling, children are empowered
to frame their understanding of multifaceted moral issues within a society.
Nolan et al. (2008) suggested that normative information could be an
underdetected source of influence on behavior. The behavior of younger African
Americans who are apparent descendants towards clinical trials continues to be affected
by the narratives that originated from the Tuskegee Study (Sacks, 2015). Storytelling can
affect behavior and when life events or experiences are considered, this process of
storytelling could create a communal experience that links the teller to listener, thereby
promoting similar behavior and attitudes (Banks-Wallace, 1998; 2002; Larkey et al.,
2015; Palacios et al., 2015). The mistrust exhibited by African Americans for healthcare
services and healthcare providers as well as other institutions has survived many
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generations. Evidence of this assumption may be found in the fact that younger African
Americans with little or no negative experience exhibit similar levels of mistrust for
clinical trials (Sacks, 2015).
An Examination of Willingness Among African Americans
African Americans differ from European Americans and other ethnic groups in
their willingness to participate in clinical trials, and this issue has been attributed to a host
of factors including a low level of trust of medical research (Meng, McLaughlin, Pariera,
& Murphy, 2016; Shavers et al., 2002). Trust has been suggested as an antecedent to
willingness (Chu, Kim, Jeong, & Park, 2015), and there is a clear distinction in the level
of trust between African Americans and other races in the United States (Meng et al.,
2016). African Americans may not be willing to participate in clinical trials due to the
influence of family members as well as fears inculcated through cultural beliefs and
folklore (Hammond, 2010; Meng et al., 2016). This idea is supported by research, which
suggested that a link exists between social factors operating within a group and their
willingness to participate in clinical trials (Meng et al., 2016).
Willingness to participate in clinical trials among African Americans includes
barrier issues related to trust, experimentation, communication, and logistics (Luebbert
and Perez, 2016). Fear and lack of trust for research were the most common barriers to
participation in clinical trials among African Americans (Hughes et al. 2015). These
barriers have been attributed to factors like lack of information related to the research and
prevailing knowledge of historical instances of unethical research practices (Hughes et
al., 2015). Other social factors like racism, attitudes towards research, fear of being used
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as guinea pigs, psychological barriers to recruitment, and socioeconomic status have also
been identified (Boulware et al., 2016; George et al., 2014; Tanner et al., 2015). Most
African Americans do not have a positive perception of safety and favorable feeling
towards clinical trials (Hughes et al., 2015). Research has shown that there is an increase
in the likelihood that a person would participate in clinical trials based on their perception
of safety, and there is a strong association between perceived wellbeing, advantageous
feeling, and willingness to participate in clinical trials (Chu et al., 2015).
Health Disparities Experienced by Black or African Americans
The Centers for Disease Control and Prevention (2017) defined disparities as the
existence of differences in the incidence, prevalence, and mortality of a disease, together
with its related adverse health outcomes, among specified populations. African
Americans represent approximately 13.3% of the U.S. population (U.S. Census Bureau,
2016) and continue to experience an unequal burden of disease, limited access to health
and health care services, and lower life expectancy when compared to other races
(Correa-de-Araujo, 2017; Frist, 2005). It is not coincidental that the African American
population is the least healthy group in the United States. Dublin (1928) stated that
“improving the health of African Americans to a state where it compares favorably with
that of Caucasians, would easily eliminate the many disabilities which plague the African
American population and improve its economic status” (p. 80). There are social factors at
work, deeply rooted in the history of African Americans in the United States, which
continue to impact the overall health of this population (Noonan et al., 2016). Social
determinants of health disparities (i.e., poverty, housing, education, access to healthcare,
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environmental exposures, and racism) continue to play a vital role in the health and
wellbeing of African Americans (Noonan et al., 2016). Racism, which is correlated with
deficiencies in education, housing, income, and access to health services, continues to
affect the overall health of this population (Noonan et al., 2016). There is evidence that
race, as a factor in health disparities, is not moderated by other factors like age, sex, and
educational level (Paradies et al., 2015). There is also documented evidence of a
relationship between perceptions of racism and mistrust for healthcare providers; the
perception of racism has been shown to have a significant negative effect on the trust and
satisfaction with care (Bankert, Peters, Clark, & Keeves-Foster, 2006).
African Americans and Participation in Clinical Trials
Although the burden of disease is higher among African Americans when
compared to other ethnic minorities, and African Americans are at a greater risk of
morbidity and early mortality (Fisher & Kalbaugh, 2011), participation of African
Americans in current clinical trials continues to be a difficult task for the drug
development industry (Fisher & Kalbaugh, 2011). There is evidence of low participation
in clinical trials among all minorities in the United States (Chen et al., 2014; Shavers et
al., 2002) with most research identifying distrust for medical research as the main cause
of the issue (Hughes et al., 2015; Luebbert & Perez, 2016; Shavers et al., 2002). The
global rates of participation in clinical trials is low, particularly among ethnic minorities
in the United States, and this issue has not seen an improvement over the years (Hughes,
et al., 2017; Lang et al., 2013). African Americans are particularly at a disadvantage from
the unintended consequence of this issue (Hughes et al., 2017).
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Quantitative and qualitative research examining the barriers and facilitators to
clinical trials participation among African Americans has revealed numerous notable
barriers. The barriers include lack of awareness regarding clinical trials, mistrust, fear of
research, and fear of adverse consequences (Corbie-Smith, Thomas, & George, 2002;
George et al., 2014; Owens, Jackson, Thomas, Friedman, & Hébert, 2013). Altruism, the
desire to help others or their community, has been identified as a one of the main
facilitators for clinical trial participation by African Americans (Shavers, 2001). Others
include access to healthcare and healthcare services, perceived risk, and compensation
(Brown & Topcu, 2003; Byrne, Tannenbaum, Glück, Hurley, & Antoni, 2014).
In a study conducted by Lang et al. (2013), they aimed at clarifying the factors
which impact African American willingness to participate in health-related research, the
researchers concluded that the willingness to participate in clinical trials exists among
this population. Their results showed that over 70% of the clinical trials naïve participants
in the study expressed willingness to participate in clinical trials (Lang et al., 2013). This
group consisted mostly of younger adults (<40 years old) who also attained a higher level
of education that the other participants. The researchers also pointed out that trust was an
impediment to participation and that participants with knowledge of the Tuskegee
Syphilis Study were 50% less likely to show willingness to participate in clinical trials
(Lang et al., 2013). Although this willingness exists, consideration must be given to the
unique sociocultural factors which exist within the African American community through
which behaviors are formed and decisions are made based on local and community
beliefs (Lee et al., 2016).
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African Americans and Distrust of the Medical Community
The various past and present medical atrocities which African Americans have
been victims of have led to a lack of trust for the medical community in the United States.
Research has shown that African Americans are less likely to participate in research and
exhibit more distrust of the medical community than any other ethnic group in the United
States (Boulware et al., 2016; Mokwunye & Nneka, 2006). There is also documented
evidence that African Americans continue to believe that the medical community,
possibly due to poor communication, do not acknowledge their perspective during their
interactions (Cuevas, O’Brien, & Saha, 2016). A combination of personal and passed-on
experiences and ongoing reiteration of doubts has led to a strong assertion of distrust over
the years in African American communities (Cuevas et al., 2016). The legacy of racism
and racial discrimination in healthcare is linked to the issue of lack of trust in medical
research among African Americans and its perception has become imbedded in the
sociocultural behavior of this population towards participation in all things related to
health and clinical trials (Boulware et al., 2016).
There are differences in the level of distrust for clinical trials among African
Americans based on age (Boulware et al., 2016); thus making it logical to assume that the
issue of distrust in medical research should reside mostly among the elderly African
Americans, who may have been directly impacted by landmark episodes of unethical
research practices, and less with the younger generation, raised in an era where stringent
regulations prevent such brash occurrences. This idea is supported by research, which
concluded that convincing older African Americans to participate in clinical trials has
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been and continues to be a difficult task, despite unfavorable health disparities that they
experience in the United States (Sabir & Pillemer, 2014). The term distrust, as used in
this research encompasses the both cultural mistrust and medical mistrust. Cultural
mistrust is defined as an inclination among African Americans to distrust European
Americans (Terrell & Terrell, 1981). Research has shown that distrust of the health care
system could be an important barrier to individuals’ willingness to seek healthcare
services, adhere to preventive health care and treatment regimens, as well as participate
in clinical trials (Rose, Peters, Shea, & Armstrong, 2004).
Patients who exhibit greater trust in their healthcare providers are more likely to
consent to participation in clinical trials (Westergaard, Beach, Saha, & Jacobs, 2014). A
widely-accepted assumption is that under-representation of African Americans in clinical
trials is a result of less willingness to participate due to mistrust and fear created by a
history of unethical practices (Stuchlik et al., 2015). There is a greater distrust for clinical
trials within the African American community when compared to the Caucasian
community (Durant et al., 2011; Fisher & Kalbaugh, 2011). This distrust among African
Americans has been attributed to the history of unethical practices and harsh treatments
that were meted out to the African Americans in the past e.g. Tuskegee Airmen Study
(Durant et al., 2011). There are many in the African American community for whom the
memories of the Tuskegee Study preserved in their thoughts and decisions related to
health care services are informed by these memories both on an individual as well as on a
group level (Doucet-Battle, 2016).
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Although distrust and socio-cultural factors have been identified as the leading
cause of the lack of or reduced willingness of African Americans to participate in clinical
trials, Anwuri et al. (2013) provided background for other potential factors, which may
play a role in the process, which leads to the decision not to participate in clinical trials.
These factors include individual-level factors like fear, faith, culture; interpersonal-level
factors like healthcare provide-patient relationship and information sharing about
research within family boundaries; institutional-level factors like physician training,
regulations, and limited minority patient pools; and public policy-level factors like
federal mandates (Anwuri et al., 2013).
The impact of knowledge regarding research cannot be diminished. Research
conducted using a hypothetical setting showed that an informed consent process which
encompasses teaching regarding the clinical trials processes and safeties currently in
place to protect subjects, increases the number of patients who are willing to
participate in clinical trials. The researchers concluded that there was a significantly
lower likelihood of patients receiving pre consent education to refer to factors like
mistrust, fear of adverse effects, absence of perceived benefits, and patient privacy as
reasons for lack of willingness to participate (Dunlop et al., 2011). Though well
recognized and widely researched with over 20 years of a statutory directive to promote
actions that increase inclusion of minorities in government-funded clinical trials, low
rates of participation of African Americans in clinical trials continues to be an issue
(Chen et al., 2014; Chu et al., 2015). This supports the conclusion by researchers of the
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existence of inherent social factors within this populations that drive low participation in
clinical trials (Chen et al., 2014).
Other Barriers to Clinical Trials Participation Among African Americans
There are various barriers that have been identified in research as the leading
factors that limit the willingness of African Americans to participate in clinical trials.
Various studies have identified the following factors as important barriers to willingness
to participate in clinical trials. These include: age, race/ethnicity, gender, socioeconomic
status, education, health status, perceived risk or benefit, altruism, distrust, and
knowledge of clinical trials (Advani et al., 2003; Boulware et al., 2016; DeFreitas, 2010;
Ding, et al., 2007; Dunlop et al., 2011; Dunn et al., 2009; Durant et al., 2011; Holman et
al., 2010; Israni et al., 2004; Lee et al., 2005; Mathews et al., 2009; Sabir & Pillemer,
2014; Shavers et al., 2002; Volkmann et al., 2009; White & Hardy, 2010). This study
focused on the barriers that are moderated or amplified by the unique sociocultural
factors which exist within the African American community. It is important to understand
the point at which altruism is overcome by fear, and how social influence lends weight to
distrust in the African American community.
Theoretical Foundation
Fishbein and Ajzen’s theory of planned behavior (TPB) served as a conceptual
framework for this study. As a well-established and recognized social cognitive theory,
the TPB has been broadly used to effectively predict and elucidate different health
behaviors and intentions to include health service utilization (Sicilia, Sáenz-Alvarez,
González-Cutre, & Ferriz, 2015). The TPB model is based on a belief that assumes that
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the intention of an individual to exhibit a behavior is an important determinant for
exhibiting that behavior (Ajzen & Madden, 1986). The extent to which an individual will
plan and develop their efforts leading to the expression of a behavior defines intention
(Ajzen & Fishbein, 1980). Intention is a motivational construct which is determined by
attitudes towards the behavior, subjective norms, and perceived behavioral control
(Ajzen, 1991); and defined as the probability that an individual will exhibit a specific
behavior in specific conditions, regardless of the outcome. The development of this
model was preceded by works of social psychologists who suggested “attitudes could
explain human actions” (Ajzen & Fishbein, 1980, p. 13). According to Ajzen and
Fishbein (1980), “people consider the implications of their actions prior to a decision to
engage or not engage in each behavior” (p. 5). The goal of TPB is to describe the
cognitive process of behaviors, focusing on a person’s choice or desire to engage in a
specific behavior (Hale, Householder, & Greene, 2002). Intention has been identified as a
significant predictor of behavior, leading to the belief that interventions must include
models that promote intention-related strategies (Doswell, Braxter, Cha, & Kim, 2011).
With consideration to external variables, which constitute the characteristics of a
behavior, a person’s trust in the outcome of a behavior determines that person’s attitude
towards that behavior (Montano & Kasprzyk, 2015).
The TPB has been utilized in research which evaluated willingness to participate
in clinical trials as the theoretical foundation. In a study conducted by Quinn et al. (2011)
to explore the application of the theory of planned behavior to patients’ decisions about
participating in a clinic trial, the results highlighted potential of the TPB as a useful tool
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for investigating psychosocial needs as they relate to behavioral intention of clinical trial
participation. This theory lends a benefit to my research because provides a perspective
that allows the researcher to evaluate individual intentions and attitudes towards
participation in clinical trials, as well as consider objective norms that influence this
behavior, thus highlighting behavioral intent. My research considered that subjective
norms are affected by an individual’s perceptions of his/her family’s and social beliefs,
i.e. a consideration of whether these close social networks will approve or disapprove of
the planned behavior (Ajzen & Fishbein, 1980). The constructs of social influence, which
exerts its impact through different routes, was measured in the framework of attitudes and
self-efficacy opportunities, intention, and past behavior (Vries et al., 1995). Social
influence was defined as an individual’s conformity, compliance, and obedience to social
factors within the community with which the individual identifies (Vries et al., 1995).
Summary
In this section, I discussed the issue of low participation in clinical trials among
African Americans in the United States, using literature to show the significance of this
issue. Though well documented in various reports, bridging this wide participation gap
has been a daunting task for both researchers and pharmaceutical companies. Social
factors which border around racism play a major role in promoting distrust of the
healthcare community. Research has identified the existence of some level of willingness
which may be diminished by the well-established beliefs developed through social
influences, storytelling, and personal experiences. Conventional methods, which involve
practices like the expansion of recruitment efforts, inclusion activities and information
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sharing, have not been effective, thus highlighting the need for a creative approach to the
identification of the antecedents to the distrust of this population for clinical trials.
Interventions to improve participation must be culturally acceptable and consider all
aspects of how distrust is learned through social interactions and storytelling. In the next
chapter, I will describe the research methods, as well as state the research questions and
hypotheses
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Chapter 3: Research Method
Introduction
In Chapters 1 and 2, I discussed the historically low rate of participation of
African Americans in clinical trials compared to other ethnicities despite multiple efforts
made by researchers and federally funded agencies to offset these differences (see
Hughes et al., 2015). Research has provided evidence that African Americans are less
willing to participate in clinical trials due to a lack of trust of the research community as
well as other socially modifiable factors (Boulware et al., 2016; Mokwunye & Nneka,
2006). In this chapter, I will discuss the quantitative research method which was used to
determine (a) the relationship between KAB towards clinical trials and African
Americans’ willingness to participate in clinical trials and (b) whether social influence
affects this group’s willingness to participate in clinical trials. The dependent variable
was willingness to participate in clinical trials, and the independent variables were social
influence and KAB towards research.
Research Questions and Hypotheses
The questions I developed for this study were primarily focused on the sociocultural factors that influence the willingness to participate in clinical trials among
African Americans aged 18 and older. The following research questions and
corresponding hypotheses guided this dissertation:
Research Question 1: What is the relationship between knowledge of clinical
trials and willingness to participate in clinical trials among African Americans?
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H01: There is no statistically significant relationship between knowledge
of clinical trials and willingness to participate in clinical trials among
African Americans.
HA1: There is a statistically significant relationship between knowledge of
clinical trials and willingness to participate in clinical trials among African
Americans.
Research Question 2: What is the relationship between attitude and beliefs and
willingness to participate in clinical trials among African Americans?
H02: There is no statistically significant relationship between attitude and
beliefs and willingness to participate in clinical trials among African
Americans.
HA2: There is a statistically significant relationship between attitude and
beliefs and willingness to participate in clinical trials among African
Americans.
Research Question 3: Does social influence within the African American
community affect the willingness of an African American to participate in clinical
trials?
H03: There is no statistically significant relationship between social
influence within the African American community and the willingness of
an African American to participate in clinical trials.
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HA3: There is a statistically significant relationship between social
influence within the African American community and willingness of an
African American to participate in clinical trials.
Study Design
I conducted this study using a cross-sectional design to determine the prevalence
of the lack of intended willingness to participate in clinical trials for this population as
well as to collect data on individual characteristics, including exposure to social factors,
alongside information about the outcome of interest. Quantitative data, in the form of a
one-time questionnaire administered by paper instrument, were collected from research
participants.
Justification for Study Design
This research design was acceptable for study because it is inexpensive and does
not require a lot of time. The cross-sectional design also allows for multiple variables at
the time data are collected as well as for outcomes and results to be analyzed to create
new theories for future research (Frankfort-Nachmias & Nachmias, 2008). The
quantitative research approach supports the research questions and allows for a higher
level of objectivity and accuracy, aggregation, quantification of data, and a concise
presentation of collective results (Lakshman et al., 2000). In addition, it is easy to design
and implement surveys needed for a cross-sectional design, and the use of standardized
surveys increases the reliability and comparability of research data (Lakshman et al.,
2000). Check and Schutt (2012) defined survey research as “the collection of information
from a sample of individuals through their responses to questions” (p. 160).
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Participants and Sampling Strategy
The target population for this study was African Americans, aged 18 years and
older, who resided in a greater metropolitan area of Ohio, and were able to sign an
informed consent form. Only participants who met the study inclusion criteria were
consented and allowed to participate in the study. I employed a sampling strategy in this
study since it was not feasible to collect data from the entire African American
population in the targeted greater metropolitan area of Ohio. Sampling strategies in
survey research aim to attain an adequate sample that is representative of the population
of interest (Ponto, 2015). To ensure a homogenous sample, the sampling frame included
the members of up to 10 predominantly African American churches. I achieved access to
this population through contact with the church leadership in person or via e-mail; they
granted the necessary approval for me to approach their congregation for participation in
this study. My initial assumption was that this approval would be granted if I provided
proper information regarding the social implications of this research study to the church
leaders. If necessary, I planned on expanding this sampling pool to include other
predominantly African American organizations as needed to meet the statistical power
requirements for the study.
With approval from the church leadership, I approached the members of the
congregation at specified times for informed consent and receipt of the surveys. To
ensure only consenting participants completed the survey, the informed consent forms
were attached to the surveys distributed to each participant. For the inclusion of the
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members of the congregation who were not present at the specified times, I also sent the
surveys via e-mail.
Sample Size Calculation
For the data analysis, I calculated a necessary sample size of 371 participants using the
formula outlined in Figure 2. For this calculation, I used data from the U.S. Census Bureau
(2016) report for the city and African American population estimate. Power analysis for a
regression analysis with two predictors was conducted in G*Power using an alpha of 0.05, a
power of 0.80, and a medium effect size (f2 = 0.15) to determine that out of the sample size of
376, a minimum of 43 responses were required to achieve 80% power.
Z2 * (p) * (1-p)
SS = ------------------c2
Z = Z value (1.96 for 95% confidence level)
p = African American population percentage > 18 years expressed as decimal (41% = .41)
c = confidence interval, expressed as decimal (.05)
Figure 2. Sample size calculation formula. p represents data from U.S. Census Bureau (2016).
Data Collection
I provided eligible participants with an informed consent form that highlighted the
objectives of the study as well as the risks and benefits of participation. Participation was
not mandated, and no names or other identifying information were collected from the
participants. Data were collected using a self-administered questionnaire, which was
distributed to members of 6 predominantly African American churches in a greater
metropolitan area of Ohio. A self-administered survey is specifically designed for
completion by participants in the research without the involvement of an interviewer
(Lavrakas, 2008). The use of self-administered questionnaires has been demonstrated to

37
be inexpensive, while requiring less involvement on the part of the researcher; it creates a
valuable and valid approach, providing clarity in the method used to explore and explain
variables and theories of interest (Ponto, 2015). I disseminated paper surveys to the
members of the church congregation who had consented to participate in this study.
Participants were allowed privacy and adequate time to complete the survey within the
church premises, and sealed submission boxes were provided to ensure the anonymity of
all submissions.
Instrumentation
For this study, I developed a survey to include the factors identified in the
literature review as having an impact on the willingness to participate in clinical trials. I
developed the survey myself because there was no readily available survey that captured
all the items needed to answer the research questions of this study. I identified four
validated scales and used them in combination to develop different sections of the survey
for this study, including: The Perceived Social Influence on Health Behavior Instrument
(PSI-HBS; Holt et al., 2010), the Distrust of the Healthcare System Scale (DHS;
Katapodi, Pierce, & Facione, 2010), the Group-Based Medical Mistrust Scale (GBMMS;
Thompson et al., 2004), and the Attitudes and Factors Affecting Young Adults’
Willingness to Participate in Clinical Research Scale (Brandt, 2013). Adequate effort was
made to ensure that proper permissions were obtained as needed for the use of these
instruments. Following the development of the new survey, an expert review panel
reviewed the survey and all feedback that I received was incorporated into the final
survey instrument.
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Description of Instruments and Validation Studies
Perceived Social Influence on Health Behavior Scale (PSI-HBS)
The PSI-HBS (Holt et al., 2010) is readily available in the public domain with no
restrictions on utilization for research purposes. The scale was developed to evaluate the
perceived part played by others in the health behavior choices and decisions of
individuals and consists of 10 items assessed in 4-point, Likert-type format (strongly
disagree, disagree, agree, and strongly agree). The researchers measured perceived
social influence on health behavior based on utilitarian influence, value-expressive
influence, and informational influence (Holt et al., 2010). The instrument has a possible
range of 10–40, with higher scores indicative of higher levels of beliefs (Holt et al.,
2010). The PSI-HBS was validated through a series of six systematic steps: review of
literature to locate existing scales, modification of existing instrument items, cultural
appropriateness and face validity review of item, item revision, finalization of instrument,
and psychometric testing of final instrument (Holt et al., 2010). Test-retest reliability was
determined by administering the instrument via telephone to a national probability
sample of 55 African Americans, and item-total correlations, internal consistency,
discriminant validity, and factorial validity were determined administering the instrument
by telephone to another national probability sample of African Americans (Holt et al.,
2010). African Americans, aged 21 years and older, living in a private residence with a
telephone were recruited by professional interviewers with contact information randomly
selected from a nationally representative pool developed based on census tract (Holt et
al., 2010). The internal consistency of the overall instrument was α = .90 (with subscales
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reported as α = .84 for utilitarian influence, α = .85 for value-expressive influence, and α
= .81 for informational influence; Holt et al., 2010).
Distrust of the Healthcare System Scale (DHS)
The DHS (Katapodi et al., 2010) is readily available in the public domain with no
restrictions on utilization for research purposes. This four-item scale addresses the
negativity and confirmatory biases, targeting distrust as an influencer of health behavior
and was developed within the framework of a study of if, and in what way, distrust of the
health system and tendency to use healthcare services influence frequency of
mammograms and clinical breast exams (Katapodi et al., 2010). The internal reliability
and convergent validity of the DHS scale were supported when administered to a
multicultural sample of 184 women (Cronbach alpha = 0.71; Katapodi et al., 2010).
Responses are made on a 4-point, Likert-type scale (strongly agree to strongly disagree)
where higher scores indicate greater distrust.
Group-Based Medical Mistrust Scale (GBMMS)
The GBMMS (Thompson et al., 2004) is readily available in the public domain
with no restrictions on utilization for research purposes. It was developed to measure
suspicion of health care systems and professionals using a 12-item Likert scale ranging
from 1 (strongly disagree) to 5 (strongly agree) with a 12 to 60 score range. Validation
was achieved in a study which investigated the psychometric properties of GBMMS and
its association with cancer screening attitudes and breast cancer screening practices
among African American and Latina women (Thompson et al., 2004). The results
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supported the validity of the scale and suggested that the scale can be used to investigate
medical mistrust (Thompson et al., 2004).
Measures
The new survey incorporated only components of existing validated instruments
which address the research questions for this study. No modifications to the wordings
were made in the new survey. The survey started with an introduction which covered the
purpose of the study, definition of clinical trials, participants’ rights to their preference to
answer or refuse to answer any of the questions, an acknowledgement of gratitude and
instructions for submitting the survey. The survey was divided into multiple sections for
ease of data collection. Appropriate Institutional Review Board approval was obtained for
the final instrument. The following measures were captured in the survey:
KAB: The survey included questions that were used to examine demographic and
informational factors which are associated with knowledge attitudes and beliefs regarding
clinical trials, as well as identified by previous research as potentially impacting
willingness to participate in clinical trials.
•

Demographic Factors: Demographic questions consisted of five items
including: age, gender, race, ethnicity, and level of education. For this study
level of education was used as a proxy for socioeconomic status. Education is
often considered a critical indicator of socioeconomic status because it
conveys information regarding earning potential across the lifespan of an
individual (Shavers, 2007; Winkleby et al., 1992).
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•

Informational Factors: According to the theory of planned behavior,
informational factors are part of the background factors that may affect an
individual’s beliefs and attitude towards clinical trials. These informational
factors are made up of knowledge acquired through both formal and informal
education. Thus, participants were asked questions to determine if they have
knowledge regarding clinical trials as well as the source of their knowledge.

Items from the survey Attitudes and Factors affecting Young Adults’ Willingness to
Participate in Clinical Research (Brandt, 2013) were utilized to capture data for this
measure.
Willingness to participate: Using a closed-ended response of “yes”, “no”, or
“don’t know” / “unsure” response, the second section of the survey examined three
different situations related to willingness to participate. These include:
•

Willingness to participate in a clinical trial related to the health of the
individual completing the survey,

•

Willingness to participate in a clinical trial related to the health of a close
friend or family member, and

•

Willingness to participate in a clinical trials study that only contributed to
scientific knowledge.

Items from the survey Attitudes and Factors affecting Young Adults’ Willingness to
Participate in Clinical Research (Brandt, 2013) were used to develop this section.
Social influence: The survey was made up of questions that aim to examine the
perceived role of others in the health behavior choices and decisions of individuals and
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consists of 10 items assessed in four-point Likert-type format (strongly disagree,
disagree, agree, strongly agree, neither disagree nor agree). Items from the PSI-HBS
(Holt et al., 2010) were used to develop this section of the survey.
Distrust: The survey included items from the GBMMS (Thompson et al., 2004)
and the DHS (Katapodiet al., 2010) to assess individual and group levels of distrust
among participants in this research study.
Data Analysis Plan
Descriptive statistics was used to characterize the study population.
Frequency/percentage were reported for categorical variables (race, gender,
socioeconomic status, education etc.) while mean and standard deviation were reported
for continuous variables (age). Our outcome of interest is willingness to participate in
clinical trials. Our predictors of interest include social influence, distrust of the health
care system, demographic and informational factors. Regression and correlation analyses
were utilized to assess if willingness is associated with any predictor of interest. A final
regression model was performed to jointly test the associations between willingness and
all the potential predictors. The regression model included the significant
predictors/variables as covariates to account for potential confounding. The study
population was characterized and the association between demographic variables and
willingness to participate in clinical trial were described. Categorical variables were
reported as percentages and for continuous variables, descriptive statistics were presented
as means with standard deviations.
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A p value adjustment can be used to control for family-wise error rate in a study
with multiple hypotheses. However, given the exploratory nature of this study, a nominal
p value threshold (p < 0.05) was applied for significance. All the analyses were
performed in the Statistical Package for Social Sciences (SPSS).
These analyses were guided by the following aims of the study and only the items
which address these aims were utilized from the validated scales:
•

Aim 1: To describe the associations between KAB and willingness to
participate in clinical trials among African Americans age 18 years and over.
Correlation analyses were employed to test the association and to examine the
direction of the association (positive or negative).

•

Aim 2: To describe the associations between social influence and willingness
to participate in clinical trials among African Americans age 18 years and
over. Correlation analyses were employed to test the association and to
examine the direction of the association (positive or negative).
Summary

In this section, I discussed the research design, study population, sample size
consideration, instrumentation, and data analysis plan. I provided a detailed review of the
planned analysis for this study which ensured that the research questions were adequately
answered. I was aware of various opportunities for additional analyses with collected
data but focused on the analyses that satisfied the current study, as well as set the stage
for future studies. In the next chapter, the results of the analyses of the data collected for
the study will be presented.
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Chapter 4: Results
Introduction
The purpose of this quantitative study was to estimate the role of social influence
in potentially diminishing the willingness of African Americans, 18 years old or older, to
participate in clinical trials. In this study, I aimed to determine (a) the relationship
between KAB towards clinical trials and African Americans’ willingness to participate in
clinical trials and (b) whether social influence affects their willingness to participate in
clinical trials. Quantitative data, in the form of a one-time questionnaire administered by
paper instrument, were collected from research participants. I measured social influence
and willingness to participate in clinical trials using items from the PSI-HBS (Holt et al.,
2010) and Attitudes and Factors Affecting Young Adults’ Willingness to Participate in
Clinical trials survey (Brandt, 2013) respectively. All survey instruments were utilized
with permissions from their respective authors.
As discussed in the previous chapter, I used a cross-sectional design to estimate
the prevalence of the outcome of interest for this population as well as to collect data on
individual characteristics, including exposure to social factors, alongside information
about the outcome of interest. This research design allowed for the inclusion of multiple
variables at the time data were collected. Regression and correlation analyses were used
to assess the relationship between willingness and any predictor of interest.
In this chapter, I will present the research questions, specific aims of the study,
data collection process, study results, and the summary of the study. Narratives will be
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used to discuss study results and answer the following research questions with the aim of
either failing to reject or rejecting the null hypothesis:
Research Question 1: What is the relationship between knowledge of clinical
trials and willingness to participate in clinical trials among African Americans?
H01: There is no statistically significant relationship between knowledge
of clinical trials and willingness to participate in clinical trials among
African Americans.
HA1: There is a statistically significant relationship between knowledge of
clinical trials and willingness to participate in clinical trials among African
Americans.
Research Question 2: What is the relationship between attitude and beliefs and
willingness to participate in clinical trials among African Americans?
H02: There is no statistically significant relationship between attitude and
beliefs and willingness to participate in clinical trials among African
Americans.
HA2: There is a statistically significant relationship between attitude and
beliefs and willingness to participate in clinical trials among African
Americans.
Research Question 3: Does social influence within the African American
community affect the willingness of an African American to participate in clinical
trials?
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H03: There is no statistically significant relationship between social
influence within the African American community and the willingness of
an African American to participate in clinical trials.
HA3: There is a statistically significant relationship between social
influence within the African American community and willingness of an
African American to participate in clinical trials.
Data Collection
I collected data for this study using a self-administered questionnaire, which was
distributed to members of 6 predominantly African American churches in a greater
metropolitan area of Ohio. Following the receipt of approval from the Walden University
Institutional Review Board (Approval Number 05-21-18-0572997), paper surveys were
distributed to the members of each church congregation, 18 years and older, who
consented to participate in this study. Out of the 10 African Methodist Episcopal
Churches approached, six agreed to allow me access to their congregation for this study.
Over a period of 12 weeks, 300 study surveys were distributed, and 119 surveys were
completed and collected. I deemed four completed surveys unusable because the
demographic and other pertinent data were missing, so these participants who did not
indicate their race and/or age were not included in the analysis. The completed surveys
were securely stored, and data from the surveys were double entered into a passwordprotected computer file for analysis. No participant identifiable information was collected
on the surveys, so no participant can be linked back to their completed survey.
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Review of Survey Responses
Demographic Factors
All respondents were African American, and there were 48 males (42%) and 67
females (58%). With an average age of 52 years, 35% (n = 40) of respondents were ages
18 to 44 years, 37% (n = 42) were ages 45 to 64 years, 22% (n = 25) were ages 65 to 74
years, and 7% (n = 8) were ages 75 years and above. Most of the respondents had
received formal education with only 14 (12.2%) reporting not having a high school
diploma or general education development (GED). Table 1 provides a detailed summary
of the demographic characteristics of the survey respondents.
Table 1
Descriptive Statistics for Demographic Variables
%

n

Male

41.7

48

Female

58.3

67

M

Gender

Age (in years)

52

18–44

34.8

40

45–64

36.5

42

65–74

21.7

25

75 and above

7.0

8

No high school diploma

12.2

14

Undergraduate degree

33.9

39

Graduate degree

15.7

18

Postgraduate degree

6.1

7

Education

Note. N = 115.

48
When asked about their health status, respondents answered that they are
generally healthy, reporting their health to be excellent (3.5%), very good (40%), good
(47.8%), and fair (8.7%). A majority of respondents reported not having an illness that
lasted more than 3 months (65.2%) and not being hospitalized in the past year (76.5%).
When asked if a family member or friend had been ill or had an illness that lasted more
than 3 months, approximately half of the respondents (52.2%) gave a positive response.
Table 2 provides details of reported health status.
Table 2
Reported Health Status
Excellent

%
3.5

n
4

Very good

40.0

46

Good

47.8

55

Fair

8.7

10

Note. N = 115.

Informational Factors
Formal education. To assess the impact of formal education in their knowledge
of clinical trials, I asked respondents about “the education I received during school
included learning about clinical trials.” Respondents (see Table 3) did not believe that the
education they received during school improved their knowledge about clinical trials with
a majority answering that they disagreed (63.5%) or strongly disagreed (13%). A smaller
number of respondents reported that they agreed (8.7%) or strongly agreed (2.6%) that
the education they received through formal schooling improved their knowledge about
clinical trials.

49
Table 3
Formal Education
%

n

The education I received during school included learning about clinical trials…
Strongly agree

2.6

3

Agree

8.7

10

Not sure

8.7

10

Disagree

63.5

73

Strongly disagree

13.0

15

Prefer not to answer

3.5

4

Note. N = 115.

To assess respondents’ knowledge of clinical trials, I presented seven questions
(i.e., three questions related to process/procedures of clinical trials and four questions
related to the informed consent process) in the survey. A review of responses to the three
questions that assessed knowledge associated with the procedures of clinical trials
revealed that a high number of the respondents were not familiar with the clinical trials
process. Twenty-one percent (n = 25) of respondents agreed that the statement “clinical
trials studies determine how well treatment works” was sometimes true, and only one
respondent (0.9%) agreed that this is always true. Similar responses were provided to the
other two questions: (a) “Clinical researchers start with a set of research questions they
want to answer before starting clinical trials studies,” with 22.6% responding sometimes
true, and only one (0.9%) responding agreed to this being always true; and (b) “In a
randomized clinical trials study, you get to choose the treatment you want,” with 16.5%
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responding sometimes true, and only one (0.9%) respondent agreed to this being always
true.
The responses to questions used to assess respondents’ knowledge of the
existence of a regulated informed consent process aimed at protecting the safety of
participants in clinical trials showed that most of the participants did not understand the
process of informed consent. Regarding awareness of participants, 19 respondents
(16.5%) agreed this is sometimes true, and one respondent (0.9%) agreed that this is
always true. Regarding awareness of potential participation risk, 13 respondents (11.3%)
agreed this is sometimes true, and no respondent agreed that this is always true.
Regarding awareness of potential benefits to participants, 20 respondents (17.4%) agreed
this is sometimes true, and no respondent agreed that this is always true. Finally,
regarding possible coercion to participate in clinical trials, 23 respondents (20%) agreed
this is sometimes true, and four respondents (3.5%) agreed that this is always true.
Overall, a high percentage of participants stated that they were unsure in all categories,
which shows a high level of misinterpretation of the regulated process of clinical trials.
Table 4 provides a complete report of respondents’ knowledge scores.
Table 4
Knowledge about Clinical Trials
n
Clinical trials studies determine how well treatment works
Prefer not to answer
23
Don’t know/unsure
63
Never
1
Rarely
2

%
20.0
54.8
.9
1.7
(table continues)
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Clinical trials studies determine how well treatment works
Sometimes
25
21.7
Always
1
.9
Clinical researchers start with a set of research questions they want to answer
before starting clinical trials studies
Prefer not to answer
22
19.1
Don’t know/unsure
63
54.8
Rarely
3
2.6
Sometimes
26
22.6
Always
1
.9
In a randomized clinical trials study, you get to choose the treatment you want
Prefer not to answer
21
18.3
Don’t know/unsure
71
61.7
Never
1
.9
Rarely
2
1.7
Sometimes
19
16.5
Always
1
.9
Told that they are participating in a research project
Prefer not to answer
10
Don’t know/unsure
73
Rarely
12
Sometimes
19
Always
1

8.7
63.5
10.4
16.5
.9

Told about the possible risks of the clinical trials study
Prefer not to answer
17
Don’t know/unsure
83
Never true
1
Rarely true
1
Sometimes true
13

14.8
72.2
.9
.9
11.3

Told how they might benefit from the clinical trials study
Prefer not to answer
26
Don’t know/unsure
65
Never true
2
Rarely true
2
Sometimes true
20

22.6
56.5
1.7
1.7
17.4
(table continues)
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Told they must participate in order to receive medical care
Prefer not to answer
7
Don’t know/unsure
52
Never true
22
Rarely true
7
Sometimes true
23
Always true
4

6.1
45.2
19.1
6.1
20.0
3.5

Note. N = 115.

Informal education. Using the following questions, I asked respondents if they
had participated or ever been asked to participate in a clinical trial to assess their
knowledge of clinical trials:
•

Prior to today, have you ever been asked to participate in a clinical trials
project?

•

Prior to today, have you ever participated in a clinical trials project?

•

To the best of your knowledge, has someone close to you, such as a family
member or friend, ever participated in a clinical trials project?

Less than a fourth of the respondents (n = 23) reported that they had been asked to
participate in a previous clinical trial (20%), and 19 respondents (16.5%) reported that
they had participated in a previous clinical trial. A small group of respondents (13.9%)
reported knowing someone close (family member or friend) who had participated in a
clinical trial. The rest of the responses included respondents who did not know or chose
not to respond. Table 5 provides additional details regarding respondents.
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Table 5
Prior participation in Clinical Trials
Previously asked to participate
Yes
No
Don’t know/unsure
Previously participated
Yes
No
Someone close participated
Yes
No
Don’t know/unsure
Prefer not to answer

n

%

23
86
5

20
74.8
4.3

19
96

16.5
83.5

16
79
19
1

13.9
68.7
16.5
.9

Note. N = 115.
Beliefs and Attitudes About Clinical Trials
To assess behavioral beliefs and attitudes about clinical trials, respondents were
asked a series of questions aimed at measuring attitudes, beliefs, and stance on clinical
trials, as well as trust in researchers. The five-item statement scale below was used to
assess attitudes and beliefs about clinical trials:
•

Clinical trials will result in cures for many diseases.

•

Research on humans goes against my religious beliefs.

•

If I donate blood, for example to the Red Cross, it would be OK with me to
use a small part of it (1 tablespoon) for research.

•

If I had surgery, I would be willing to allow the use of some of my surgical
tissue for clinical trials.

•
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I would allow my name to be put on a registry or list to be contacted for future
research.

Individual item scores were added to produce a raw score, which was used to
calculate the percent score. According to the scoring system specified by the developer
Al-Jumah et al. (2011), positive attitude statements were scored from 5 (strongly agree)
to 1 (strongly disagree). Percent score greater than 60% were considered positive attitude
while a score less than 60% score was considered negative. The sample mean was 53.4%
(median = 52%, SD = 12.31), thus indicating that most respondents had a negative
attitude towards clinical trials (72%). Based of review of individual scores, most of the
respondents agreed that clinical trials will result in cures for many diseases (52.2%) and
reported that clinical trials do not go against their religious beliefs (49.6%). Most
respondents would allow use of some of their blood in research (60%), as well as tissue
(52.2%). Most respondents reported that they would allow their names to be added to a
registry for future research contact (31.3%). Table 6 below shows the individual scores.
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Table 6
Beliefs and Attitudes About Clinical Trials

Clinical trials will result in cures for many diseases
Strongly agree
Agree
Not sure
Disagree
Strongly disagree
Prefer not to answer
Research on humans goes against my religious beliefs
Strongly agree
Agree
Not sure
Disagree
Strongly disagree
Prefer not to answer
If I donate blood, for example to the Red Cross, it would be OK
with me to use a small part of it (1 tablespoon) for research
Strongly agree
Agree
Not sure
Disagree
Strongly disagree
Prefer not to answer
If I had surgery, I would be willing to allow the use of some of my
surgical tissue for clinical trials
Strongly agree
Agree
Not sure
Disagree
Strongly disagree
Prefer not to answer
I would allow my name to be put on a registry or list to be contacted
for future research
Strongly agree
Agree
Not sure
Disagree
Strongly disagree
Prefer not to answer
Note. N = 115.

n

%

22
60
22
7
0
4

19.1
52.2
19.1
6.1
0
3.5

1
17
14
57
22
4

.9
14.8
12.2
49.6
19.1
3.5

20
69
7
13
6
0

17.4
60.0
6.1
11.3
5.2
0

20
60
16
18
0
1

17.4
52.2
13.9
15.7
0
.9

17
36
32
27
2
1

14.8
31.3
27.8
23.5
1.7
.9
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In addition to measuring attitudes and beliefs, respondents were also asked if they
favor or oppose the use of human beings for clinical trials. Responses were based on a 5point Likert scale (5 = strongly favor, 4 = favor, 3 = neutral, 2 = oppose, 1 = strongly
oppose). Most of the respondents reported that they were neutral to this question (40.9%)
and a handful (11.3%) were not sure. To review the positive responses, a combination of
“strongly favor” and “favor” responses indicated that about half of the respondents
(40.9%), favored the use of humans in clinical trials. Table 7 provides the details of
responses.
Table 7
Favoring Human Score

In general, would you say that you favor or oppose the use of
human beings for clinical trials?
Strongly favor
Favor
Neutral
Oppose
Strongly oppose
Don’t know/unsure

n

%

6
41
47
6
2
13

5.2
35.7
40.9
5.2
1.7
11.3

Note. N = 115.

Social Influence on Health Behavior
Respondents were asked a series of questions to assess to evaluate the perceived
part played by others in the health behavior choices and decisions. These 10 items were
assessed in 4-point Likert-type format (1 = strongly disagree, 2 = disagree, 3 = agree, 4 =
strongly agree). Perceived social influence on health behavior was measured based on
utilitarian influence, value-expressive influence, and informational influence. The
instrument has a possible range of 10–40, with higher scores indicative of higher levels of
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beliefs (Holt et al., 2010). The responses to the 10 survey questions were totaled to
produce raw scores. Respondents social influence on behavior scores ranged from 10 to
30 (mean = 20.77; SD± = 4.11). These scores indicate that, in general, respondents’
health behaviors are impacted by social influence. A review of the individual responses
showed that majority of respondents (55%) will seek advice from friends regarding health
behaviors for which they have limited knowledge. Table 8 below provides details on
individual responses.
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Table 8
Social influence on health behavior
n
%
I rarely engage in health behaviors until I am sure my friends approve of them
Strongly disagree
28
24.3
Disagree
69
60.0
Agree
15
13.0
Strongly agree
3
2.6
It’s important that others agree with my health lifestyle (before I act)
Strongly Disagree
23
20.0
Disagree
68
59.1
Agree
17
14.8
Strongly agree
2
1.7
Missing
5
4.3
When engaging in health behaviors, I generally do things that I think others will
approve of.
Strongly disagree
31
27.0
Disagree
75
65.2
Agree
9
7.8
Strongly agree
0
0
I like to know what health behaviors make good impressions on others
Strongly disagree
18
15.7
Disagree
70
60.9
Agree
27
23.5
Strongly Agree
0
0
I achieve a sense of belonging by making the same healthy choices that others do
Strongly Disagree
27
23.5
Disagree
67
58.3
Agree
16
13.9
Strongly agree
4
3.5
Missing
1
.9
If I want to be like someone, I often try to make the same healthy choices that they
do
Strongly disagree
26
22.6
Disagree
62
53.9
(table continues)
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If I want to be like someone, I often try to make the same healthy choices that they
do
Agree
23
20.0
Strongly agree
3
2.6
Missing
1
.9
I often identify with other people by making the same healthy choices that they do
Strongly disagree
26
22.6
Disagree
72
62.6
Agree
15
13.0
Strongly agree
2
1.7
If I have little experience with a health behavior, I often ask my friends about it
Strongly disagree
17
14.8
Disagree
40
34.8
Agree
55
47.8
Strongly agree
3
2.6
I often consult other people to help choose the best alternative available for a health
behavior
Strongly disagree
18
15.7
Disagree
45
39.1
Agree
49
42.6
Strongly agree
3
2.6
I frequently gather information from friends and family before I engage in a health
behavior
Strongly disagree
7
6.1
Disagree
55
47.8
Agree
48
41.7
Strongly agree
5
4.3
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Measuring Distrust of Healthcare System
The level of distrust of the healthcare system was evaluated using a four-item
DHS, developed by Katapodi et al., 2010) and a 12-item GBMMS developed by
Thompson et al. (2004). For the DHS, responses are made on a 4-point Likert-type
scale (strongly agree to strongly disagree) with a 4 to 16 score range, where higher
scores indicate greater distrust. For the GBMMS, possible responses were scored from 5
(strongly agree) to 1 (strongly disagree) with a 12 to 60 score range (higher scores
indicating higher level of distrust). The responses to the questions in each scale were
totaled to produce raw scores. A review of the DHS responses showed that respondents’
distrust for health care providers scores ranged from 5 to 13 (mean = 8.53; SD± = 1.546).
These scores indicate that, in general, respondents’ do not have high level of trust for
their health care providers. The GBMMS results review showed scores ranging from 18
to 46 (mean = 32.59; SD± = 3.651), indicating, like the DHS, that respondents have a low
level of trust for health care providers. A review of the individual responses from the
DHS showed that 70% of respondents disagree, and 15.7% strongly disagree with the
statement “I trust my health care providers.” In the GBMMS, 39% of the respondents did
not believe that African Americans received the same care from doctors and health care
workers as people from other ethnic groups. Table 9 provides details on individual
responses for both scales.
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Table 9
Measuring Distrust in Health Care Providers
n

%

I trust my healthcare providers
Strongly disagree
18
15.7
Disagree
81
70.4
Agree
5
4.3
Strongly agree
11
9.6
I always believe someone when they say that their healthcare provider
hasn’t been nice to them
Strongly disagree
6
5.2
Disagree
64
55.7
Agree
40
34.8
Strongly agree
5
4.3
In general, the healthcare system is not sensitive to the patients’ needs.
Strongly disagree
12
10.4
Disagree
65
56.5
Agree
33
28.7
Strongly agree
4
3.5
I’ve been treated poorly by healthcare providers often more than I’ve
been treated with respect
Strongly disagree
25
21.7
Disagree
85
73.9
Agree
4
3.5
Strongly agree
1
.9
People from my ethnic group cannot trust doctors and health care
workers
Strongly disagree
15
13.0
Disagree
34
29.6
Neither
48
41.7
Agree
10
8.7
Strongly agree
8
7.0
People from my ethnic group should be suspicious of information from
doctors and health care workers
Strongly disagree
8
7.0
Disagree
54
47.0
Neither
41
35.7
Agree
8
7.0
Strongly agree
4
3.5
(table continues)
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People from my ethnic group should not confide in doctors and health
care workers because it will be used against them
Strongly disagree
22
19.1
Disagree
66
57.4
Neither
20
17.4
Agree
5
4.3
Strongly agree
2
1.7
People from my ethnic group should be suspicious of modern medicine
Strongly disagree
20
17.4
Disagree
61
53.0
Neither
23
20.0
Agree
10
8.7
Strongly agree
1
.9
Doctors and health care workers treat people of my ethnic group like
“guinea pigs
Strongly disagree
16
13.9
Disagree
50
43.5
Neither
29
25.2
Agree
15
13.0
Strongly agree
5
4.3
Doctors and health care workers do not take the medical complaints of
people of my ethnic group seriously
Strongly disagree
7
6.1
Disagree
59
51.3
Neither
32
27.8
Agree
15
13.0
People of my ethnic group are treated the same as people of other
groups by doctors and health care workers
Strongly disagree
3
2.6
Disagree
36
31.3
Neither
23
20.0
Agree
43
37.4
Strongly agree
8
7.0
People of my ethnic group receive the same care from doctors and
health care workers as people from other groups
Strongly Disagree
4
3.5
Disagree
35
30.4
Neither
31
27.0
Agree
35
30.4
Strongly Agree
10
8.7
(table continues)
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In most hospitals, people of different ethnic groups receive the same
kind of care
Strongly disagree
5
4.3
Disagree
25
21.7
Neither
31
27.0
Agree
36
31.3
Strongly agree
18
15.7
Doctors have the best interests of people of my ethnic group in mind
Strongly disagree
6
5.2
Disagree
17
14.8
Neither
43
37.4
Agree
36
31.3
Strongly agree
13
11.3
Doctors and health care workers sometimes hid information from
patients who belong to my ethnic group
Strongly disagree
8
7.0
Disagree
36
31.3
Neither
32
27.8
Agree
35
30.4
Strongly agree
4
3.5
I have personally been treated poorly or unfairly by doctors or health
care workers because of my ethnicity
Strongly disagree
16
13.9
Disagree
63
54.8
Neither
17
14.8
Agree
16
13.9
Strongly agree
3
2.6
Note. N = 115.

The Stated Intention of Willingness to Participate
For this study, three scenarios which have varying levels of risks were used to
measure individual’s willingness to participate in clinical trials. For each scenario,
respondents’ perception of the physical risk associated with clinical trials was measured
using the following responses on a Likert scale: “very safe”, “safe”, “neutral”, “risky”, or
“very risky”. These were followed by questions regarding willingness to participate based
on personal health benefit, adding to scientific knowledge, and benefit to someone close.
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•

Scenario 1 – You are asked to participate in a clinical trials study that
consisted of taking a small amount of blood out of my arm

•

Scenario 2 – You are asked to participate in a clinical trials study that
consisted of cutting off a small amount of skin (about the size of a pencil
eraser), called a biopsy. This would require an injection (shot) of numbing
medicine so that you did not have any pain and two to three sutures (stitches).
The biopsy would be on a place where the scar would not be seen, such as
you’re the top of your hip. There may be mild discomfort or pain for one to
two days.

•

Scenario 3 – You are asked to participate in a clinical trials study that
consisted of taking a medication (drug) that will have some side effects from
the medicine, such as feeling sick to your stomach (nausea) or throwing up
(vomiting).

For Scenario 1 (blood draw), most respondents thought that it was safe (48.7%).
Majority of the respondents asserted that they would be willing to take part in such
research to benefit their own health (64.3%) and benefit the health of someone close to
them (70.4%). However, willingness among respondents was decreased if the study only
contributed to scientific knowledge (41.7%). Majority of the respondents (30%) thought
that $50 was fair compensation for the stated scenario and assumed risk.
For Scenario 2 (skin biopsy), respondents were evenly split on their assessment of
the risk; safe (27.8%) vs. risky (28.7%). With regards to a benefit to their health,
approximately half of the respondents (51%) expressed willingness to participate, one
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third (33%) expressed willingness to participate to contribute to scientific knowledge, and
over half (53.9%) expressed willingness to participate if it benefited someone close. The
response to a “fair” compensation was almost evenly split between the choice of $100
and $500 among respondents ($100 = 33% and $500 = 26.1%).
For Scenario 3 (drug trial), majority of the respondents did not believe this was
safe (risky = 38.3%; very risky = 25.2%). Only less than a fourth of the respondents
(15.7%) thought it was either safe or very safe to take a drug with some side effects.
About one third expressed willingness to participate to benefit their own health (31%),
over half of respondents would not be willing to participate to add to scientific
knowledge (54%), and about half of the respondents would be willing to participate to
benefit someone close (43%). Majority of the respondents (40%) thought that the highest
compensation ($500) was fair and commensurate with the risk. This was followed by a
third of the respondents (26.1%) who thought $100 compensation was fair.
Table 10
Measuring Willingness to Participate and Compensation
n
%
Do you think the physical risk (the chance of being hurt or injured in this study) of
this study is
Very risky
1
.9
Risky

11

9.6

Neutral

31

27.0
(table continues)

Do you think the physical risk (the chance of being hurt or injured in this study) of
this study is
Safe

56

48.7

Very safe

13

11.3

66
Prefer not to answer

3

2.6

If you were asked today, would you be willing to take part in this clinical trial
project if you felt it WOULD benefit your health now or in the future?
Yes
74
64.3
No

23

20.0

Don’t know/unsure

14

12.2

Prefer not to answer

4

3.5

If you were asked today, would you be willing to take part in this clinical trial
project if it would NOT benefit your health now or in the future but will add to
scientific knowledge?
Yes
48
41.7
No

33

28.7

Don’t know/unsure

29

25.2

Prefer not to answer

5

4.3

If you were asked today, would you be willing to take part in a study that you felt
would NOT benefit YOUR health but would benefit the health of SOMEONE
CLOSE TO YOU?
Yes
81
70.4
No

14

12.2

Don’t know/unsure

19

16.5

Prefer not to answer

1

.9

If a person was willing to participate in Scenario 3, what do you think would be
FAIR compensation?
No compensation
9
7.8
$5

8

7.0

$10

10

8.7

$50

38

33.0

$100

26

22.6
(table continues)

If a person was willing to participate in Scenario 3, what do you think would be
FAIR compensation?
Prefer not to answer

24

20.9
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Do you think the physical risk (the chance of being hurt or injured in this study) of
this study is
Very risky
12
10.4
Risky

33

28.7

Neutral

27

23.5

Safe

32

27.8

Very safe

5

4.3

Prefer not to answer

6

5.2

If you were asked today, would you be willing to take part in this clinical trial
project if you felt it WOULD BENEFIT YOUR health now or in the future?
Yes
59
51.3
No

25

21.7

Don’t know/unsure

26

22.6

Prefer not to answer

5

4.3

If you were asked today, would you be willing to take part in this clinical trial
project if it would NOT benefit your health now or in the future but will add to
scientific knowledge?
Yes
38
33.0
No

48

41.7

Don’t know/unsure

28

24.3

Prefer not to answer

1

.9

If you were asked today, would you be willing to take part in a study that you felt
would NOT benefit YOUR health but would benefit the health of SOMEONE
CLOSE TO YOU?
Yes
62
53.9
No

25

21.7

Don’t know/unsure

28

24.3
(table continues)
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If a person was willing to participate in Scenario 2, what do you think would be
FAIR compensation?
No compensation
1
.9
$5

9

7.8

$25

13

11.3

$100

38

33.0

$500

30

26.1

Prefer not to answer

24

20.9

Do you think the physical risk (the chance of being hurt or injured in this study) of
this study is…?
Very risky
29
25.2
Risky

44

38.3

Neutral

17

14.8

Safe

17

14.8

Very safe

1

.9

Prefer not to answer

7

6.1

If you were asked today, would you be willing to take part in this clinical trial
project if you felt it WOULD benefit your health now or in the future?
Yes
31
27.0
No

36

31.3

Don’t know/unsure

45

39.1

Prefer not to answer

3

2.6

If you were asked today, would you be willing to take part in this clinical trial
project if it would NOT benefit your health now or in the future but will add to
scientific knowledge?
Yes
19
16.5
No

54

47.0

Don’t know/unsure

39

33.9

Prefer not to answer

3

2.6
(table continues)
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If you were asked today, would you be willing to take part in a study that you felt
would NOT benefit YOUR health but would benefit the health of SOMEONE
CLOSE TO YOU?
Yes
43
37.4
No

25

21.7

Don’t know/unsure

44

38.3

Prefer not to answer

3

2.6

If a person was willing to participate in Scenario 3, what do you think would be
FAIR compensation?
No Compensation
3
2.6
$5

6

5.2

$25

5

4.3

$100

30

26.1

$500

46

40.0

Prefer not to answer

25

21.7

Research Questions
The theory of planned behavior, which serves as the conceptual framework for
this study, highlights the existence of a linear path from KAB, to the intention of
willingness to participate, to participation. Associations between knowledge, social
beliefs and attitudes and willingness to participate in clinical trials were tested.
RQ 1: What is the relationship between knowledge of clinical trials and willingness to
participate in clinical trials among African Americans?
H01: There is no statistically significant relationship between knowledge of
clinical trials and willingness to participate in clinical trials among African
Americans.
HA1: There is a statistically significant relationship between knowledge of clinical
trials and willingness to participate in clinical trials among African Americans.
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As described earlier, three scenarios, with perceived physical risk increasing from
the first to the third, were presented to the participants (Scenario 1: a blood draw;
Scenario 2: a biopsy, an injection and sutures; and Scenario 3: anticipated side effects).
Using response choices of “yes”, “no”, and “don’t know/unsure”, the following questions
assessed the willingness to participate in three situations within each scenario: a) if the
research would benefit that individual’s health, b) if the research would benefit the health
of someone close to them, and c) if the research add to scientific knowledge. Total scores
were computed for responses to the survey questions used to assess willingness as well as
the survey questions used to assess knowledge of clinical trials. Higher scores in each
case indicated a higher level of willingness and greater knowledge of clinical trials
respectively. Regression and correlation analyses were utilized to test the association
between knowledge of clinical trials and willingness to participate in trial.
A Pearson Correlation (see Table 11) was used to test the relationship between
Knowledge score 1 (three questions which assessed knowledge associated with the
procedures of clinical trials) and Knowledge score 2 (four questions related to the
informed consent process), and the overall willingness to participate score. The result
showed a negative correlation between Knowledge 1 (-0.063) and Knowledge 2 (-0.045)
and willingness to participate. Based on these results, we can accept the null hypothesis
that there is no statistically significant relationship between knowledge of clinical trials
and willingness to participate in clinical trials among African Americans. Knowledge of
the procedures of clinical trials (p = 0.501) and the informed consent process (p = 0.635)
is not a valuable predictor of overall willingness to participate in clinical trials.
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Table 11
Correlation Analysis of Knowledge of Clinical Trials and Willingness to Participate

Knowledge

Pearson Correlation

Score 1

Knowledge Score 1

Willingness Score

1

-.063

Sig. (2-tailed)

Willingness
Score

.501

N

115

115

Pearson Correlation

-.063

1

Sig. (2-tailed)

.501

N

115

115

Knowledge Score 2
1

Willingness Score
-.045

Knowledge

Pearson Correlation

Score 2

Sig. (2-tailed)

.635

N

115

115

Willingness

Pearson Correlation

-.045

1

Score

Sig. (2-tailed)

.635

N

115

115

A linear regression analysis (see Table 12) was also conducted using
“willingness” as the dependent variable, and the results showed that the R in the Model
Summary equals Pearson Correlation. R-squared, which examines the goodness of fit,
was 0.4% and 0.2% respectively, indicating a very poor goodness of fit. The regression
coefficient shows that for each increase in knowledge by 1, there will be a decrease in
willingness by 0.086 and 0.099 respectively.
Table 12
Regression Analysis of Knowledge of Clinical Trials and Willingness to Participate
Model Summary

Model
1

R

R Square

Adjusted R Square

.063a

.004

-.005

72
Std. Error of the Estimate
5.006

a. Predictors: (Constant), Knowledge Score

Coefficientsa

Model
1

(Constant)
Knowledge Score

Unstandardized

Standardized

Coefficients

Coefficients

B

Std. Error

19.791

1.108

-.086

.128

Beta

-.063

t

Sig.

17.862

.000

-.675

.501

a. Dependent Variable: Willingness

Additional analyses were conducted to test the association between knowledge of
the procedures of clinical trials and each individual research scenario described earlier,
used to assess willingness (Table 13). The results showed a negative correlation between
knowledge and willingness in Scenario 1 and 3, and a positive correlation in Scenario 2.
The results were consistent with the conclusion that knowledge of the procedures of
clinical trials is not a valuable predictor of willingness to participate in clinical trials for
Scenarios 1 and 2 (p = 0.620; 0.227). However, for Scenario 3, the results showed that
knowledge of the procedures of clinical trials is a good predictor of willingness to
participate in clinical trials which involve a higher risk to the participant (p = 0.010).
Table 13
Correlation Analysis of Knowledge of Clinical Trials and Willingness to Participate (All
Scenarios)
Knowledge Score 1 Willingness Scenario 1
Knowledge
Pearson Correlation
1
-.047
Score

Sig. (2-tailed)
N

.620
115

115
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Willingness

Pearson Correlation

-.047

Scenario 1

Sig. (2-tailed)

.620

N

115

Knowledge

Pearson Correlation

Score

Sig. (2-tailed)

1

115

Knowledge Score 1 Willingness Scenario 2
1
.114
.227

N

115

115

Willingness

Pearson Correlation

.114

1

Scenario 2

Sig. (2-tailed)

.227

N

115

Knowledge

Pearson Correlation

Score

Sig. (2-tailed)

115

Knowledge Score 1 Willingness Scenario 3
1
-.238*
.010

N

115

115

-.238*

1

Willingness

Pearson Correlation

Scenario 3

Sig. (2-tailed)

.010

N

115

115

*Correlation is significant at the 0.05 level (2-tailed).

Analysis of the association between knowledge of the informed consent process in
clinical trials and each individual research scenario also supported the conclusion that
knowledge is not a valuable predictor of willingness to participate in clinical trials.
Details of the p values are presented in Table 14.
Table 14
Correlation Analysis of Knowledge of Clinical Trials and Willingness to Participate (All
Scenarios)
Knowledge

Pearson Correlation

Score

Sig. (2-tailed)

Knowledge Score 2
1

Willingness Scenario 1
-.022
.814

74
N

115

115

Willingness

Pearson Correlation

-.022

1

Scenario 1

Sig. (2-tailed)

.814

N
Knowledge

Pearson Correlation

Score

Sig. (2-tailed)

115
Knowledge Score 2
1

115
Willingness Scenario 2
.048
.610

N

115

115

Willingness

Pearson Correlation

.048

1

Scenario 1

Sig. (2-tailed)

.610

N
Knowledge

Pearson Correlation

Score

Sig. (2-tailed)

115
115
Knowledge Score 2 Willingness Scenario 3
1
-.143
.126

N

115

115

Willingness

Pearson Correlation

-.143

1

Scenario 1

Sig. (2-tailed)

.126

N

115

115

RQ 2: What is the relationship between attitude and beliefs and willingness to participate
in clinical trials among African Americans?
H02: There is no statistically significant relationship between attitude and beliefs
and willingness to participate in clinical trials among African Americans.
HA2: There is a statistically significant relationship between attitude and beliefs
and willingness to participate in clinical trials among African Americans
The results of a Pearson Correlation (Table 15) analysis of attitude and beliefs
score and overall willingness score showed a positive correlation (0.357) between attitude
and beliefs and willingness to participate in clinical trial (p = 0.000). This was confirmed
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by the regression analysis (p = 0.000), and a regression coefficient which shows that for
each increase in attitude and beliefs by 1, will result in an increase in willingness by
0.449.
Table 15
Pearson Correlation Analysis of Attitude and Beliefs Score and Overall Willingness
Score
Attitude/Belief

Pearson Correlation

Score

Sig. (2-tailed)

Attitude/Belief Score
1

.000

N
Willingness

Willingness
.357**

Pearson Correlation

115

115

.357**

1

Sig. (2-tailed)

.000

N

115

115

**. Correlation is significant at the 0.01 level (2-tailed).

Model Summary
Model
R
1

R Square

Adjusted R Square

Std. Error of the Estimate

.127

.119

4.687

.357a

a. Predictors: (Constant), Attitude/Belief Score

Coefficientsa

Model
1

Unstandardized

Standardized

Coefficients

Coefficients

B

Std. Error

(Constant)

8.925

2.549

Attitude/Belief Score

.449

.111

Beta

.357

t

Sig.

3.501

.001

4.057

.000

a. Dependent Variable: Willingness

Based on these results we can reject the null hypothesis in lieu of the alternative
hypothesis that there is a statistically significant relationship between attitude and beliefs
and willingness to participate in clinical trials among African Americans. Attitude and
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beliefs about clinical trials is a good predictor of willingness to participate in clinical
trials (p = 0.000).
RQ 3: Does social influence within the African American community affect the
willingness of an African American to participate in clinical trials?
H03: There is no statistically significant relationship between social influence
within the African American community and the willingness of an African American to
participate in clinical trials.
HA3: There is a statistically significant relationship between social influence
within the African American community and willingness of an African American to
participate in clinical trials.
Understanding the impact of social influence on the willingness of African
Americans to participate in clinical trials was the focus of this research question. Survey
question used to assess social influence were obtained from the perceived social
Influence on health behavior instrument which has a possible range of 10–40, with higher
scores indicative of higher levels of beliefs. Pearson Correlation was used to test the
association between perceived social Influence on health behavior score and willingness
to participate score. As shown in Table 16, there was a negative correlation (-0.141)
between social influence and willingness to participate in clinical trial, but with no
statistical significance (p = 0.132). This was confirmed by the regression analysis (p =
0.132), and a regression coefficient which shows that for each increase in attitude and
beliefs by 1, will result in a decrease in willingness by 0.172. Based on these results, we
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can accept the null hypothesis that there is no statistically significant relationship between
social influence and willingness to participate in clinical trials among African Americans.
Table 16
Correlation Analysis of Social Influence and Willingness to Participate in Clinical Trials
PSI_HB SCORE

PSI_HB SCORE
1

Pearson Correlation

Willingness
-.141

Sig. (2-tailed)

Willingness

Model Summary
Model
1

.132

N

115

115

Pearson Correlation

-.141

1

Sig. (2-tailed)

.132

N

115

R

R Square

.357a

.127

Adjusted R Square

115

Std. Error of the Estimate

.119

4.687

a. Predictors: (Constant), PSI_HB Score

Coefficientsa

Model
1

(Constant)
PSI_HB Score

Unstandardized

Standardized

Coefficients

Coefficients

B

Std. Error

22.684

2.396

-.172

.113

Beta

-.141

t

Sig.

9.468

.000

-1.519

.132

a. Dependent Variable: Willingness

Additional analyses were conducted to test the association between social
influence and each individual research scenario described earlier, used to assess
willingness. The results for Scenarios 2 and 3 were consistent with the conclusion that
social influence is not a valuable predictor of willingness to participate in clinical trials (p
= 0.943; 0.085). However, for Scenario 1, which represents the least risk to a research
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participant, the results showed that social influence is a good predictor of willingness to
participate in clinical trials (p = 0.047).
Table 17
Correlation analysis of Social Influence and Willingness to Participate in Clinical Trials
(All Scenarios)
PSI_HB SCORE
Willingness Scenario 1
PSI_HB SCORE
Pearson Correlation
1
-.185*
Sig. (2-tailed)

.047

N

115

115

-.185*

1

Willingness

Pearson Correlation

scenario 1

Sig. (2-tailed)

.047

N

115

115

Summary
In this chapter, I provided a detailed overview and interpretation of the study
results. Three research questions were evaluated using statistical analysis. The first
research question evaluated the relationship between knowledge of clinical trials and
willingness to participate in clinical trials among African Americans. The results showed
that knowledge is not a valuable predictor of willingness to participate in clinical trials.
The second research question evaluated the relationship between attitude and beliefs and
willingness to participate in clinical trials among African Americans. The results showed
that attitudes and beliefs about clinical trials is a good predictor of willingness to
participate in clinical trials. The third research question evaluated the impact of social
influence within the African American community on the willingness of an African
American to participate in clinical trials. The results showed that social influence is a
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good predictor of willingness to participate in clinical trials in trials that pose minimal
risks to participants. Discussion of the findings will be presented in chapter 5.
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Chapter 5: Discussion, Conclusions, and Recommendation
Introduction
The purpose of this quantitative study was to form a discussion regarding social
influence and its impact on the willingness of African Americans, 18 years or older, to
participate in clinical trials. I collected quantitative data, in the form of a one-time
questionnaire administered by paper instrument, from research participants over a period
of 12 weeks from June to August 2018. Social influence and willingness to participate in
clinical trials were measured using items from the PSI-HBS (Holt et al., 2010) and
Attitudes and Factors affecting Young Adults’ Willingness to Participate in Clinical
Research survey (Brandt, 2013), respectively. In this study, I collected and analyzed data
to address three research questions and corresponding hypothesis. Data were analyzed
using correlation and regression analysis in SPSS. My aim was to understand the
relationship between African Americans’ KAB towards clinical trials and willingness to
participate in clinical trials and whether social influence affects their willingness to
participate in clinical trials.
Interpretation of Findings
The conceptual framework that I used for this study was Fishbein and Ajzen’s
TPB. The use of this well-established and recognized social cognitive theory was
applicable to this study because the model is based on beliefs that assume that the
intention of an individual to exhibit a behavior is an important determinant for exhibiting
that behavior (see Ajzen & Madden, 1986). The TPB provided a perspective that allowed
me to evaluate individual intentions and attitudes towards participation in clinical trials as
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well as consider objective norms that influence this behavior. In this study, I considered
that subjective norms are affected by an individual’s perceptions of their family and
social beliefs (i.e., a consideration of whether these close social networks will approve or
disapprove of the planned behavior; see Ajzen & Fishbein, 1980). The constructs of
social influence were measured in the framework of attitudes and self-efficacy
opportunities, intention, and past behavior (see Vries et al., 1995). Social influence was
defined as an individual’s conformity, compliance, and obedience to social factors within
the community with which the individual identifies (Vries et al., 1995).
Knowledge of Clinical Trials and Willingness to Participate
A majority of the survey respondents did not believe that the education they
received during school improved their knowledge about clinical trials (76.3%), were not
familiar with the clinical trial process, and did not understand the process of informed
consent. Only a small percent of participants reported having prior knowledge of clinical
trials through their own or a family member’s participation. Researchers that examined
the relationship between knowledge of clinical trials and willingness to participate and
reported a positive correlation (i.e., Advani et al., 2003; Boulware et al., 2016; DeFreitas,
2010) concluded that individuals who are more knowledgeable about issues related to
clinical trials have more favorable attitudes toward clinical trials and are more willing to
contemplate participation in a clinical trial (Ojukwu et al, 2018). However, for the first
research question, I concluded that there is no statistically significant relationship
between knowledge of clinical trials and willingness to participate in clinical trials among
the African Americans surveyed for this study. Knowledge of the procedures of clinical
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trials (p = 0.501) and the informed consent process (p = 0.635) were not valuable
predictors of willingness to participate in clinical trials.
Attitude and Beliefs and Willingness to Participate
To assess behavioral beliefs and attitudes about clinical trials, I asked respondents
a series of questions aimed at measuring their attitudes, beliefs, and stance on clinical
trials as well as their trust in researchers. Previously, other investigators have concluded
that African Americans have more negative attitudes about clinical trials and as a result
are less willing to participate (Pariera, Murphy, Meng, & McLaughlin, 2017). These
negative attitudes are mostly fueled by the lack of trust in health care providers and an
increasing interest in complementary and alternative medicine (Pariera et al., 2017).
The findings from this study suggest that the respondents’ attitudes and beliefs
were associated with their willingness to participate in clinical trials. There was a positive
correlation (0.357) between attitudes and beliefs and willingness to participate in clinical
trial (p = 0.000). This was confirmed by the regression analysis (p = 0.000), and a
regression coefficient that shows that for each increase in attitudes and beliefs by 1, an
increase in willingness by 0.449 will result. There is a statistically significant relationship
between attitudes and beliefs and willingness to participate in clinical trials among
African Americans. Attitudes and beliefs about clinical trials are a good predictor of
willingness to participate in clinical trials (p = 0.000).
Social Influence and Willingness to Participate
Understanding the impact of social influence on the willingness of African
Americans to participate in clinical trials was the focus of this study. I obtained the
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survey questions used to assess social influence from the PSI-HBS, which has a possible
range of 10–40, with higher scores indicative of higher levels of beliefs. A Pearson
correlation was used to test the association between PSI-HBS score and willingness to
participate score. For the analysis, which included perceived social influence and all
scenarios of clinical trials, the result was a negative correlation (-0.141) between social
influence and willingness to participate in clinical trial but with no statistical significance
(p = 0.132). This was confirmed by the regression analysis (p = 0.132), and a regression
coefficient that shows that for each increase in perceived social influence by 1, a decrease
in willingness by 0.172 will result. However, analyses to test the association between
perceived social influence and each individual research scenario revealed that for
Scenario 1, which represents the least risk to a research participant, social influence is a
good predictor of willingness to participate in clinical trials (p = 0.047). Based on this
finding, I rejected the null hypothesis in lieu of the alternative hypothesis that there is a
statistically significant relationship between social influence and willingness to
participate in clinical trials with minimal risk among African Americans.
Limitations
There were limitations to this research. The response rate limited access to the
desired study population. Only 115 participants completed the survey, which created a
limitation since the analysis required a larger sample size to accurately detect statistically
significant relationships between variables. The participants in this study were not
representative of the entire African American population in a greater metropolitan area of
Ohio because only church attendees who agreed to the research were included. Although
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a previous study reported that religiously based differences on social issues are less
evident among African-Americans compared to the overall population, with 53% of
African Americans polled reporting attending religious services at least once a week
(Sahgal & Smith, 2016), the result of this study may not be generalizable to the entire
African American population because of differences in opinions that may exist among
church goers vs. non-church goers. Another limitation was that all indication of
willingness to participate in clinical trial was based on hypothetical scenarios, which may
lead to responses that may not accurately reflect the individuals’ intention or future action
(see Schoenberg & Ravdal, 2000). In the conduct of this study, there were variables
whose presence could affect the variables of focus. A final limitation was that the
analyses used in this study did not effectively control for these variables which were
potential confounders.
Recommendations
The results from this study provide evidence of the existence of a relationship
between social influence and willingness to participate in clinical trials involving
minimal risk among African Americans. In this study, I only evaluated responses from a
small non-representative sample of African Americans, but future research should utilize
a broader inclusion of this population and other ethnicities to efficiently detect this
relationship. Confounders should be clearly identified and controlled in future research
using Multivariate methods because there is a high potential for confounding even after
data adjustment, leading to unjustified results. Additional analyses should also be
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conducted to understand the roles played by socioeconomic factors in the process of
formulating and retaining social norms in this population.
Implications for Social Change
Failure to increase the participation rates of African Americans in clinical trial
will inhibit the progress of clinical trial research into novel and effective methods in drug
development (Frew et al., 2015). I designed this study to identify how social influence
affects African Americans’ willingness to participate in clinical trials as a platform for
the development and implementation of interventions to improve clinical trial
participation among this population. Researchers involved in the development of novel
therapies can use the information from this study to improve the clinical trial patient
recruitment process. A clear understanding of these social factors and how they interact
to impact the health behavior of African Americans will create a path to the development
of viable and sustainable intervention.
Conclusion
The purpose of this quantitative study was to identify the interactions between
social influence and the intended willingness of African Americans to participate in
clinical trials. The findings may be used as a platform for the development and
implementation of interventions aimed at improving clinical trials participation among
this population. In this study, I examined and elucidated the potential association between
social influence and willingness of African Americans to participate in clinical trials. The
results were in line with findings from existing literature; however, more research is
needed to gain a better understanding of how social influence is developed and fostered
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in the African American community. African Americans deserve the chance to be
represented in the process of developing therapies aimed at treating diseases that burden
their community, and the results of this study create a starting point for more research to
emerge from.
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